Secor Capital Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Secor Capital Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,813	Closed	-$468K	–	562
2018 Q2	$468K	Sell	7,813 -28,268	-78%	-$1.46M	0.04%	395
2018 Q1	$1.65M	Buy	36,081 +18,504	+105%	+$772K	0.14%	235
2017 Q4	$700K	Buy	+17,577	New	+$695K	0.03%	325
2016 Q1	–	Sell	-33,249	Closed	-$447K	–	752
2015 Q4	$447K	Buy	+33,249	New	+$514K	0.13%	271
2015 Q3	–	Sell	-40,967	Closed	-$696K	–	605
2015 Q2	$696K	Buy	+40,967	New	+$583K	0.25%	146

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Secor Capital Advisors's SUPN Position: Q3 2018 in Review

Secor Capital Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 7,813 shares — an estimated $468K sold.

Secor Capital Advisors first reported a position in SUPN in Q2 2015 and held it in 5 quarters. The position peaked at $1.65M in Q1 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

Secor Capital Advisors reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Secor Capital Advisors sold 7,813 Supernus Pharmaceuticals shares in Q3 2018, an estimated $468K.
Secor Capital Advisors first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Secor Capital Advisors's Supernus Pharmaceuticals position peaked at $1.65M in Q1 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on Secor Capital Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.